These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8697006)

  • 21. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.
    Hino M; Kobayashi Y; Wada M; Hattori Y; Kurahasi T; Nakagawa H
    J Obstet Gynaecol Res; 2016 Nov; 42(11):1613-1617. PubMed ID: 27785897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
    Edelman DZ; Anteby SO; Peretz T
    Harefuah; 1996 Jul; 131(1-2):31-6. PubMed ID: 8854476
    [No Abstract]   [Full Text] [Related]  

  • 24. Ifosfamide in the treatment of ovarian cancer.
    Markman M
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Paclitaxel should be included in standard therapy of ovarian carcinoma].
    Tropé C; Kaern J; Saeter G; Gore M
    Tidsskr Nor Laegeforen; 2003 Nov; 123(21):3083-4. PubMed ID: 14618184
    [No Abstract]   [Full Text] [Related]  

  • 26. [CA-125 as response parameter in ovarian carcinoma].
    Zirpel I; Illiger HJ
    Strahlenther Onkol; 2000 Apr; 176(4):200. PubMed ID: 10841742
    [No Abstract]   [Full Text] [Related]  

  • 27. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A
    Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
    [No Abstract]   [Full Text] [Related]  

  • 28. Application effect of humanized nursing in the treatment of ovarian cancer with paclitaxel and cisplatin.
    Wang X; Fan H
    Panminerva Med; 2023 Jun; 65(2):262-263. PubMed ID: 34060277
    [No Abstract]   [Full Text] [Related]  

  • 29. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
    Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
    J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel and lung cancer: new preparation. No therapeutic progress.
    Prescrire Int; 2000 Apr; 9(46):38-40. PubMed ID: 11503783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel in the treatment of ovarian cancer.
    Kavanagh JJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
    Oestreicher P
    ONS Connect; 2007 Apr; 22(4):24-5. PubMed ID: 17477008
    [No Abstract]   [Full Text] [Related]  

  • 33. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Paclitaxel, a new anticancer drug].
    Jekunen A; Lehtovirta P; Pyrhönen S
    Duodecim; 1994; 110(13):1235-40. PubMed ID: 7497933
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NICE approves Taxol for ovarian cancer.
    Kmietowicz Z
    BMJ; 2000 May; 320(7245):1293. PubMed ID: 10807610
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of ovarian cancer. An impressive history of improvement in survival and quality of life.
    Markman M
    Oncology (Williston Park); 2006 Apr; 20(4):347-54; discussion 354, 357-8, 364 passim. PubMed ID: 16683414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.